Small Molecule Drug Substance Outsourcing Drivers by Company Size

In Q3 2021, ISR surveyed 124 sponsors who outsource small molecule drug substance manufacturing to learn more about their primary reason for outsourcing. The data show that sponsors from large pharma tend to use CMOs to augment internal manufacturing capacity (66%) while sponsors from non-large pharma use CMOs for all manufacturing needs (58%).